Platelet Hyperreactivity Project

Completed

• Conditions: Platelet Reactivity

• Registration Number: NCT00976196
• Lead Sponsor: Pierre Fontana

Brief Summary

The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients.

Detailed Description

The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients using a system biology approach that include proteomics analysis of selected platelet sub-fractions in patients displaying extreme phenotype.

Main objective:

* to characterize the proteome profile of platelet hyperreactivity in aspirin-treated cardiovascular patients

Secondary objectives:

* to characterize the platelet hyperreactivity phenotype in cardiovascular patients treated with aspirin

* to determine genetic polymorphisms associated with platelet hyperreactivity

Study Timeline

• Study Start: 2009-01
• Study First Submitted: 2009-09-11
• Study First Submitted QC: 2009-09-11
• Study First Posted: 2009-09-14
• Primary Completion: 2010-01
• Study Completion: 2010-01
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-01
• Last Update Posted: 2015-12-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

• Documented symptomatic ischemic atherothrombotic disease treated by aspirin.

Exclusion Criteria

• Known platelet disorder
• Chronic treatment by antiplatelet drugs other than aspirin
• Chronic anticoagulant treatment
• Chronic non steroidal anti-inflammatory drug treatment
• Active cancer
• Treatment with serotonin reuptake inhibitors

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
proteome profile of platelet hyperreactivity	cross sectional	to characterize the proteome profile of platelet hyperreactivity in aspirin-treated cardiovascular patients

Secondary Outcome Measures

Name	Time	Method
platelet hyperreactivity phenotype in cardiovascular patients treated with aspirin	cross sectional

Trial Locations

Locations (1)

University Hospital Geneva; 🇨🇭 Geneva, Switzerland